Navigation Links
Roche Statement Regarding Tamiflu U.S. Label Revision

NUTLEY, N.J., March 4 /PRNewswire/ -- Roche has informed healthcare professionals that the prescribing information for Tamiflu (oseltamivir phosphate) has been updated to reflect recommendations made by the FDA Pediatric Advisory Committee at a November 27, 2007 meeting regarding neuropsychiatric events. The revision is an update to a label change made in November of 2006 and includes information that influenza itself has been associated with a variety of neuropsychiatric events and that these reports appear to be uncommon.

The changes to the label reflect observations from a growing body of data, which shows no evidence of a causal relationship between Tamiflu and the reported events. The data shows that these neuropsychiatric adverse events also occurred in flu patients who were not taking Tamiflu. In fact, emerging evidence suggests that influenza itself may cause neuropsychiatric adverse events. In addition to clinical trials conducted prior to the approval of Tamiflu by the FDA, extensive post-marketing studies have been conducted and additional research is underway by Roche, Chugai and the Japanese health authority.

Roche agrees that it is important that healthcare professionals and patients know that all children with flu should be monitored, regardless of whether they are taking an antiviral medication. If any sign of unusual behavior is observed, a healthcare professional should be contacted immediately.

Antivirals like Tamiflu play an important role in the prevention and treatment of influenza. Tamiflu has been used by more than 48 million people worldwide, including nearly 21 million children, since its approval in 1999. Tamiflu is approved for the treatment and prevention of influenza in patients over one year of age and is one of two antiviral medications recommended by the CDC for the 2007-2008 influenza season.

Roche is committed to ensuring safe and appropriate use of our medications and will continue to conduct appropriate post-marketing monitoring and research.

For full U.S. prescribing information, please visit

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Neurochem announces departure of two members of management team
2. Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
3. Press Statement: Roche Affirms That Tamiflu(R) is in Ample Supply Nationwide
4. Roche Completes Tender Offer for Ventana Shares
5. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
6. Roche Purchases Shares in Tender Offer for Ventana
7. Mayo Clinic Seeks Mitigation for Rochester as Condition of Canadian Pacific - DM&E Railroad Merger
8. Roche Plans to Complete Ventana Offer on February 7th
9. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
10. Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4, 2008
11. Roche Engages in Four Additional AIDS Technology Transfers to Strengthen Local Manufacturing in Worlds Poorest Countries
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... continuing education course in Dallas, TX, on January 29 and 30, 2016. The ... improve the functions of their practices, to learn how to better succeed in ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... a key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus ... Georgia State University. , Their study showed that small molecule analogs that target ...
(Date:11/30/2015)... ... November 30, 2015 , ... Dr. Seth D. Margulies ... locations, patients can visit Dr. Margulies to experience the best available orthodontic experience in ... title of "NJ Top Dentist"! , Orthodontics is the branch of dentistry that specializes ...
(Date:11/30/2015)... ... 2015 , ... ”Dying Words: The AIDS Reporting of Jeff Schmalz and How ... coincide with World AIDS Day. The multi-media project will be in audio documentary form ... he was dying of the disease. , A collaborative effort led by author, professor ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Reports magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer Reports as ... more so for a child’s exposure limits. , The original Nov 2015 CR ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... KONG, Nov. 30, 2015 (HK$,000)For the Six Months Ended 30 September 2015 ... Income , 421,979 , 384,242 , ... , 34,719 , (18.3) Medical Insurance ... , 16.1 Medical Devices and Accessories Sales , ... Chinese Herbal Medicines Sales , 2,822 , ...
(Date:11/30/2015)... Calif. , Nov. 30, 2015 /PRNewswire/ ... the norm in U.S. medical imaging is ... increasingly popular accountable care payer-provider contracts are ... and, in their wake, alter provider-vendor relationships. ... payments will push forward new purchasing frameworks ...
(Date:11/30/2015)... Nov. 30, 2015 Oramed Pharmaceuticals Inc. (NASDAQ: ... the development of oral drug delivery systems, announced today ... at up to $50,000,000 with Hefei Tianhui Incubator of Technologies Co., Ltd. ... capsule, ORMD-0801, in China , ... . The agreements were signed at the Israel ...
Breaking Medicine Technology: